DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines

Completed

• Conditions: Diabetes Mellitus Type 2; Crestor, Rosuvastatin; LDL Cholesterol; Observational

• Registration Number: NCT00233649
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-05
• Study First Submitted: 2005-10-05
• Study First Submitted QC: 2005-10-05
• Study First Posted: 2005-10-06
• Status Verified: 2010-11
• Last Update Submitted: 2010-11-18
• Last Update Posted: 2010-11-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2500

Inclusion Criteria

• Diabetes Mellitus Type 2, LDL-C > 2,5 mmol/l, no cholesterol lowering medication used last 3 months, starts with Crestor 10 mg, permission to use patient data by AZ

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Research Site; 🇳🇱 Zwolle, Netherlands